Rebekah Wharton

Dr. Rebekah Wharton

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2021 in Journal of Analytical Toxicology
Verified
Journal Article
Open access
PDF file
RWRebekah Wharton
Rebekah Wharton
JCJerry Casbohm
Jerry Casbohm
RHRyan Hoffmaster
Ryan Hoffmaster
BBBobby N Brewer
Bobby N Brewer
MFM G Finn
M G Finn
RJRudolph C Johnson
Rudolph C Johnson
Health-care workers, laboratorians and overdose prevention centers rely on commercial immunoassays to detect the presence of fentanyl; however, the cross-reactivity of fentanyl analogs with these kits is largely unknown. To address this, we conducted a pilot study evaluating the detection of 30 fentanyl analogs and metabolites by 19 commercially available kits (9 lateral flow assays, 7 heterogeneous immunoassays and 3 homogenous immunoassays). The analogs selected for analysis were compiled from the Drug Enforcement Administration and National Forensic Laboratory Information System reports from 2015 to 2018. In general, the immunoassays tested were able to detect their intended fentanyl analog and some closely related analogs, but more structurally diverse analogs, including 4-methoxy-butyryl fentanyl and 3-methylfentanyl, were not well detected. Carfentanil was only detected by kits specifically designed for its recognition. In general, analogs with group additions to the piperidine, or bulky rings or long alkyl chain modifications in the N-aryl or alkyl amide regions, were poorly detected compared to other types of modifications. This preliminary information is useful for screening diagnostic, forensic and unknown powder samples for the presence of fentanyl analogs and guiding future testing improvements.

13 December 2019 in Toxins
Verified
Journal Article
Open access
PDF file
RWRebekah Wharton
Rebekah Wharton
BCBrady Cunningham
Brady Cunningham
ASAdam Schaefer
Adam Schaefer
SGSophia M. Guldberg
Sophia M. Guldberg
EHElizabeth I Hamelin
Elizabeth I Hamelin
RJRudolph C. Johnson
Rudolph C. Johnson
Microcystins (MC) and nodularin (NOD) are toxins released by cyanobacteria during harmful algal blooms. They are potent inhibitors of protein phosphatases 1 and 2A (PP1 and PP2A) and cause a variety of adverse symptoms in humans and animals if ingested. More than 250 chemically diverse congeners of MCs have been identified, but certified reference materials are only available for a few. A diagnostic test that does not require each reference material for detection is necessary to identify human exposures. To address this need, our lab has developed a method that uses an antibody to specifically isolate MCs and NOD from urine prior to detection via a commercially available PP2A kit. This assay quantitates the summed inhibitory activity of nearly all MCs and NOD on PP2A relative to a common MC congener, microcystin-LR (MC-LR). The quantitation range for MC-LR using this method is from 0.050–0.500 ng/mL. No background responses were detected in a convenience set of 50 individual urines. Interday and intraday % accuracies ranged from 94%–118% and relative standard deviations were 15% or less, meeting FDA guidelines for receptor binding assays. The assay detected low levels of MCs in urines from three individuals living in close proximity to harmful algal blooms (HABs) in Florida.

22 August 2018 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
RWRebekah Wharton
Rebekah Wharton
GOGeovannie Ojeda-Torres
Geovannie Ojeda-Torres
BCBrady Cunningham
Brady Cunningham
MFMelanie C. Feyereisen
Melanie C. Feyereisen
KHKasey L. Hill
Kasey L. Hill
RJRudolph C. Johnson
Rudolph C. Johnson

21 November 2022 in Toxins
Verified
Journal Article
Open access
PDF file
BCBrady Cunningham
Brady Cunningham
RWRebekah Wharton
Rebekah Wharton
CLChristine Lee
Christine Lee
MMMike A. Mojica
Mike A. Mojica
LKLogan C. Krajewski
Logan C. Krajewski
EHElizabeth I Hamelin
Elizabeth I Hamelin
Microcystins are toxic chemicals generated by certain freshwater cyanobacteria. These chemicals can accumulate to dangerous levels during harmful algal blooms. When exposed to microcystins, humans are at risk of hepatic injury, including liver failure. Here, we describe a method to detect microcystins in human plasma by using immunocapture followed by a protein phosphatase inhibition assay. At least 279 microcystins have been identified, and most of these compounds share a common amino acid, the Adda side chain. We targeted this Adda side chain using a commercial antibody and extracted microcystins from human samples for screening and analysis. To quantitate the extracted microcystins, we fortified plasma with microcystin-LR, one of the most well-studied, commonly detected, and toxic microcystin congeners. The quantitation range for the detection of microcystin in human plasma using this method is 0.030–0.50 ng/mL microcystin-LR equivalents. This method detects unconjugated and conjugated forms (cysteine and glutathione) of microcystins. Quality control sample accuracies varied between 98.9% and 114%, with a precision of 7.18–15.8%. Finally, we evaluated plasma samples from a community health surveillance project of Florida residents living or working near harmful algae blooms.

10 January 2025 in ACS Nano
Verified
Journal Article
Open access
ACAsheley Chapman
Asheley Chapman
MXMinghao Xu
Minghao Xu
MSMichelle Schroeder
Michelle Schroeder
JGJason M. Goldstein
Jason M. Goldstein
ACAsiya Chida
Asiya Chida
MFM. G. Finn
M. G. Finn
Structural variants of the synthetic opioid fentanyl are a major threat to public health. Following an investigation showing that many derivatives are poorly detected by commercial lateral flow and related assays, we created hapten conjugate vaccines using an immunogenic virus-like particle carrier and eight synthetic fentanyl derivatives designed to mimic the structural features of several of the more dangerous analogues. Immunization of mice elicited strong antihapten humoral responses, allowing the screening of hundreds of hapten-specific hybridomas for binding strength and specificity. A panel of 13 monoclonal IgG antibodies were selected, each showing a different pattern of recognition of fentanyl structural variations, and all proving to be highly efficient at capturing parent fentanyl compounds in competition ELISA experiments. These results provide antibody reagents for assay development as well as a demonstration of the power of the immune system to create binding agents capable of both broad and specific recognition of small-molecule targets.

22 May 2026 in Prevention Science
Verified
Journal Article
Closed access
PDF file
JAJessica L. Armstrong
Jessica L. Armstrong
RWRebekah Wharton
Rebekah Wharton